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Abstract
Background: Sperm protein 17 (Sp17) is a highly conserved mammalian protein in the testis and spermatozoa and
has been characterized as a tumor-associated antigen in a variety of human malignancies. Many studies have
examined the role of Sp17 in tumorigenesis and the migration of malignant cells. It has been proposed as a useful
target for tumor-vaccine strategies and a novel marker to define tumor subsets and predict drug response. This
study aimed to investigate the expression of Sp17 in endometrial and cervical cancer specimens, its possible
correlation with the pathological characteristics, and its value in the diagnosis and immunotherapy of the related
cancers.
Methods: The monoclonal antibodies against human Sp17 were produced as reagents for the analysis and
immunohistochemistry was used to study two major kinds of paraffin-embedded gynecological cancer specimens,
including 50 cases of endometrial cancer (44 adenous and 6 adenosquamous) and 31 cases of cervical cancer (15
adenous and 16 squamous). Normal peripheral endometrial and cervical tissues were used as controls.
Results: Sp17 was found in 66% (33/50) of the patients with endometrial cancer and 61% (19/31) of those with
cervical cancer. Its expression was found in a heterogeneous pattern in the cancer tissues. The expression was not
correlated with the histological subtype and grade of malignancy, but the staining patterns were different in
endometrial and cervical cancers. The hyperplastic glands were positive for Sp17 in the normal peripheral
endometrial and cervical tissues in 10% (8/81) of the patients.
Conclusions: Sp17 is highly expressed in human endometrial and cervical cancers in a heterogeneous pattern.
Although the expression frequency of Sp17 is not correlated with the histological subtype, the staining pattern
may help to define endometrial and cervical cancers. Sp17 targeted immunotherapy of tumors needs more
accurate validation.
Background
Endometrial cancer and cervical cancer are two of the
most common malignancies among females globally [1].
Some of them have a poor prognosis due to their che-
moresistance and early metastasis. No specific molecular
markers are currently available for the early diagnosis
and immunotherapy of these aggressive malignancies
[2]. Therefore, there is an urgent need to identify tumor
antigens associated with chemoresistance and early
metastasis which can then be used as suitable targets for
immunotherapy.
The immunogenic protein, Sperm protein 17 (Sp17), is
a member of the cancer testis antigen (CTA) family and
has been extensively characterized [3-12]. Sp17 is a
highly conserved mammalian protein in the testis and
spermatozoa of humans and animals including rabbits,
mice, baboons, and macaques [13-15]. Human Sp17 has
151 amino acids and an apparent molecular mass of
24.5 kDa [3]. It is comprised of 3 different domains: an
N-terminal domain that has 45% homology to a type II
regulatory subunit of protein kinase A-anchoring pro-
tein, a central domain that contains a sulfated- carbohy-
drate-binding domain, and a C-terminal domain that
has 43% homology to a Ca
2+-calmodulin-binding
domain [4,16]. The function of Sp17 is not yet comple-
tely understood; it is thought to potentially play a role
in regulating sperm maturation, capacitation, acrosomal
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any medium, provided the original work is properly cited.reaction, and interactions with the oocyte zona pellucida
during the fertilization process [17,18].
The expression of Sp17 in malignant cells was first
discovered by Dong et al [19] who found the mouse
homologue of Sp17 to be highly expressed in metastatic
cell lines derived from a murine model of squamous cell
carcinoma but not in the nonmetastatic parental line.
Various works have demonstrated the aberrant expres-
sion of Sp17 in cancers of unrelated histological origin,
including multiple myeloma, ovarian cancer, nervous
system tumors and esophageal squamous cell cancer
[[6,7], and [10]]. A possible role for Sp17 in cancer was
demonstrated in transformed lymphoid and hematopoie-
tic cells. As Sp17 mediates cell adhesion and interaction,
it was thought to be involved in the migration of malig-
nant cells [18,20]. Other authors and our results demon-
strated that its overexpression decreased the
chemosensitivity of ovarian cancer cells in vitro [20,21].
Moreover, Bumm et al showed that Sp17 could be used
as a means of discriminating between 2 subsets of pri-
mary esthesioneuroblastomas [22].
Human Sp17 was thought to be expressed at low
levels in normal tissues other than the testis. Zhang et
al [9] used a combination of real time PCR and immu-
nohistochemistry to investigate the distribution of Sp17
on a large panel of normal tissues and demonstrated the
restricted normal tissue expression of Sp17. Their
results showed that although Sp17 transcripts could be
detected in some normal tissues by PCR, the levels of
expression were <2% of those in normal testis. Sp17
protein was detected only in the testis but not in any
other normal tissues by immunohistochemistry with two
Sp17 murine monoclonal antibodies, each directed at a
non-overlapping B-cell epitope. Thus, the immunogeni-
city and restricted expression in normal tissues made
Sp17 an attractive molecule for the immunotherapeutic
procedure of associated cancers [23-26].
In a phase I study, Sp17-pulsed dendritic cells in Sp17
+ cancer patients were shown to kill HLA-matched
tumor cell lines and fresh tumor cells presenting Sp17
epitopes. In addition, treatment with cytotoxic T lym-
phocytes (CTL) did not show any apparent side effects
in Sp17+ tumor animal models [27]. These findings
have implications for the translational development of
safe and effective T-cell-based therapies for human
ovarian cancer. Gynecological cancers would be the best
candidates for Sp17 targeted immunotherapy, since
Sp17 expression may be lowest in women.
Other investigators, however, propose that the tissue
distribution of Sp17 in humans is more complex than
originally thought. Sp17 has been found in human
somatic cells, such as the ciliated epithelia of the
respiratory airways and both male and female reproduc-
t i v es y s t e m s[ 2 8 ] ,s y n o v i o c y t e so fp a t i e n t sw i t h
rheumatoid arthritis [29], and in the melanophages of
cutaneous melanocytic lesions [30]. These findings have
r a i s e daq u e s t i o na st ow h e t h e rS p 1 7m a yb eau s e f u l
target for tumor immunotherapy.
We found in our previous work that Sp17 was aber-
rantly expressed in 43% of human epithelial ovarian can-
cer tissues [20], but its presence in two other
gynecological cancers, endometrial and cervical has not
been examined. The aim of this study was to investigate
the frequency of the Sp17 expression at the protein level
and its cell distribution and localization in various histo-
logical subtypes of endometrial and cervical cancers and
to analyze its utility as a target for tumor diagnosis and
antigen-specific immunotherapy in these patients.
Methods
Patient Specimens
A panel of formalin-fixed paraffin-embedded gynecologi-
cal tumor specimens was obtained from the archival
resource of the Department of Pathology of Jinling Hos-
pital, which included 50 cases of endometrial cancer
(EMC) and 31 cases of cervical cancer (Table 1). The
positive control samples were collected from the testis
tissue of an elderly prostatic cancer patient and from
the ejaculated spermatozoa of patients at semen exami-
nation. All tumors were classified according to the
WHO criteria. All data, including the age of the patient
and histological type and grade of the tumor, were
obtained from pathological records. To determine
whether Sp17 was expressed at the protein level in non-
pathological tissues another 81 specimens were taken
from the periphery of the lesions. The absence of patho-
logical cells or tissues was subsequently confirmed by
microscopy. The study protocol was approved by the
Ethics Committee of the Hospital and informed consent
was obtained from all patients included in the study.
Generation of Sp17 Monoclonal Antibodies
Recombinant Sp17 and its monoclonal antibodies were
produced as previously described [31]. Briefly, the
nucleotide sequence encoding Sp17 was amplified from
human testicular RNA and cloned in pET-28a(+) (Nova-
gen) containing an N-terminal 6-histidine fusion tag.
Table 1 Characteristics of the patients
Tumor histological
subtype
Patients,
n
Mean age (range),
yr
Positive,
n (%)
Endometrial cancer 50 54 (34-71) 33 (66.0)
Adenocancer 44 54 (34-71) 29 (66.0)
Adenosquamous cancer 6 49 (34-57) 4 (66.7)
Cervical cancer 31 46 (17-72) 19 (61.3)
Adenocancer 15 40 (26-56) 7 (46.7)
Squamous cancer 16 50 (17-72) 12 (75.0)
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After lysis of the bacteria Sp17 was purified via nickel
affinity chromatography. The recombinant Sp17 protein
was used to immunize BALB/c mice for generating
monoclonal antibody-producing hybridomas. The hybri-
doma supernatants were screened by ELISA for the pre-
sence of antibodies and the hybridoma cell lines
producing antibodies against the recombinant Sp17 pro-
tein were cloned. The specificity of these antibodies was
then confirmed by immunohistochemistry of natural
Sp17 from the human testis and ejaculated spermatozoa.
Monoclonal antibodies were purified from hybridoma
ascites using a HiTrap Protein G HP affinity column
(Amersham Biosciences).
Immunohistochemistry
Tissue sections (3 μm) were placed on glass slides,
heated at 60°C for 20 min, and then deparaffinized with
xylene and ethanol. For antigen retrieval, tumor
specimens mounted on glass slides were immersed in
preheated antigen retrieval solution (DAKO high pH
solution; DAKO) for 20 min and cooled for another 20
min at room temperature. After the inactivation of
endogenous peroxidase, 2 μg/ml 3C12 antibody was
added and incubated overnight at 4°C. The primary
Figure 1 Production of recombinant human Sp17 and specific
identification of hSp17 mAbs by Western blot. A. SDS-PAGE
analysis of recombinant human Sp17; B. Specific identification of
hSp17 mAb 3C12 by Western blot. Protein from human testis (B1)
and ejaculated spermatozoa (B2).
Figure 2 Immunohistochemical characteristics of the Sp17 monoclonal antibody. a. testis from an old patient with prostatic cancer; b.
ejaculated spermatozoa; c. EMC staining before blocking; d. EMC staining after blocking.
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(DAKO). Diaminobenzidine (DAB) substrate was added
for 7 min followed by washing with deionized water,
and hematoxylin was applied for 1 min to counterstain
t h et i s s u es e c t i o n s .T h et i s s u es e c t i o n sw e r ed e h y d r a t e d
with graded ethanol followed by xylene and the cover-
slips were attached with permount. The immunohisto-
chemical reaction was evaluated in 5 areas of the slide
sections under the light microscope at 40× and 100×
objective magnifications and semi-quantitatively graded
by two expert pathologists. The extent of immunohisto-
chemical reactivity was graded as follows: negative; +,
5-25% of the cells stained; + +, >25-50% of the cells
stained; + + +, >50-75% of the cells stained; and + + + +,
>75% of the cells stained. The negative control slides
omitting the primary antibody were included in all
assays. The cancer specificity of the binding of the
Sp17 antibody was confirmed in competitive binding
assays using soluble recombinant Sp17 protein.
Statistical Analysis
All statistical analyses were performed with the SPSS
software. Differences in proportions were evaluated by
Fisher’s exact test as appropriate. Statistical correlations
between Sp17 expression and pathological parameters
(such as the histological subtype and grade of tumor)
were calculated using the Kruskal-Wallis test. Results
were considered statistically significant at the P <0 . 0 5
level.
Results
Production of Recombinant Sp17 Protein and Its
Monoclonal Antibodies
Successful production of recombinant Sp17 was demon-
strated by SDS-PAGE, which showed a protein of the
expected size of around 30 kDa. Following passage
through the Ni-NTA affinity column and numerous
rounds of washing the recombinant protein was purified
(Fig 1A) and used for generating the monoclonal
Figure 3 Immunohistochemistry of Sp17 in the EMC tissues (A-C) and cultured cell line (D). The expression of Sp17 was heterogeneous: A.
confertim; B. scattered. C. Sp17 was localized in the cytoplasm and nucleus, with enplaque; D. Sp17 was localized in the cytoplasm, nucleus and
membrane. (A, B 10×; C, D 40× original magnification, 100× inset).
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chemistry assay. Two hybridoma cell lines (3C12 and
3D6) secreting mAb against Sp17 were developed (Fig
1B). The 3C12 monoclonal antibody exhibited intense
immunostaining in the human testis (Fig 2a) and ejacu-
lated spermatozoa (Fig 2b). The specific binding of the
Sp17 antibody to EMC cells was further confirmed in a
competitive binding (blocking) assay, which showed the
abrogation of staining when the Sp17 antibodies were
pre-incubated with 100 μg/ml soluble recombinant Sp17
proteins (Fig 2c, 2d).
Immunohistostaining of Sp17
A total of 81 archival gynecological malignancy speci-
mens were investigated by immunohistochemistry. Posi-
tive staining was observed in 52 (64%) of the 81 cancer
samples. 66% (33/50) of all the samples in EMC were
Sp17 positive; 61% (19/31) in cervical cancer, 47% (7/15)
in adenocancer and 75% (12/16) in squamous cancer.
T a b s2a n d3s h o wt h ef r e q u e n c i e so fS p 1 7e x p r e s s i o n
at the protein level in EMC and cervical cancer with dif-
ferent histological types and differentiated degrees. The
statistics show no significant differences among all
groups. Sp17 expression was also observed in 10% (8/
81) of hyperplastic gland cells in peripheral endometrial
and cervical tissues.
The Sp17 protein was strongly expressed in the ade-
nous, adenosquamous and squamous cancer cells of the
epithelial malignancies (Figs 3 and 4). The expression
patterns of Sp17 in gynecological tumors were always
heterogeneous. The density of Sp17 expression was dif-
ferent from one patient to another. Staining revealed
mainly enplaque in endometrial cancers (Fig 3) and
granulo in cervical cancers (Fig 4). In keeping with
Figure 4 Immunohistochemistry of Sp17 in cervical cancer tissues (A-C) and hyperplastic gland (D). The staining pattern of Sp17 was
granulo in all the original cervical tissues and located in the cavosurface of adenocancer and the hyperplastic gland. A. squamous cancer; B, C,
adenocancer; D. hyperplastic glands in the periphery of the lesions. Sp17 was localized in the cytoplasm but had different intensity. (A, B, D, 20×;
C, 40× original magnification, 100× inset).
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mainly localized in the cytoplasm of a variable number
of tumor cells with positive staining of the cell nucleus
and membrane. To corroborate the immunohistochem-
ical findings the localization of Sp17 was also deter-
mined in the cultured ovarian cell line HO8910 which
overexpressed Sp17 by DNA transfection in our labora-
tory [20]. The photomicrograph in Fig 3D shows Sp17
immunoreactivity in the cytoplasm, nucleus, and mem-
brane of HO8910 cells.
Discussion and Conclusions
T oa s s e s st h ed i a g n o s t i ca n dimmunotherapeutic utility
of Sp17 for gynecological cancers the present compre-
hensive analysis of Sp17 was undertaken on two kinds
of gynecological malignancies. We examined Sp17
expression in tumors by IHC. The results showed the
presence of Sp17 in various gynecological epithelia can-
cers, including 66% (33/50) of EMC and 61% (19/31) of
cervical cancer in Chinese patients. The present study is
the first to show the expression of Sp17 at the protein
level in a high proportion of endometrial cancer and
cervical cancers. The results of our study, together with
previous findings, show a high positive rate of Sp17
expression in ovarian cancer, in 68% of cells at the
mRNA level [11] and 43% of cells at the protein level
[20]. These data suggest that Sp17 was highly expressed
in gynecological epithelial cancers.
We investigated the distribution of Sp17 in tissues and
its immunolocalization in cells and found that it was
positive but with different intensity and density in all
kinds of gynecological epithelial cancers, including ade-
nous, adenosquamous, and squamous cancers. It was
even in a few hyperplastic glands in normal peripheral
tissues. Although it had a high total positive rate, Sp17
was expressed in a low density in half of the positive tis-
sues (Tables 2 and 3). In adenocancer and hyperplastic
glands Sp17 was located in the cavosurface (Figs 3 and
4). We also found different staining patterns of Sp17,
with enplaque in endometrial cancer but granulo in cer-
vical cancer and the cervical hyperplastic gland. This
may help to define tumors of the two different origins.
Sp17 expression showed no correlation with the histolo-
gical subtypes and grades of tumors of the same origin.
The immunolocalization in cancer cells was related to
the physiological function and potential of Sp17 as a tar-
get for in vivo imaging diagnosis and immunotherapy of
tumors. Its heterogeneous expression was demonstrated
in the cytoplasma, nucleus and cell surface. Although
Sp17 is not easily identified in the cell membrane of
gynecological cancer tissues, its presence can be con-
firmed in a cultured cell line (Fig 3).
Our previous study revealed that overexpression of
Sp17 in the ovarian cancer cell line HO8910 increased
cellular migration, suggesting that Sp17 might enhance
tumor progression [20]. However, the relationship
Table 2 Sp17 expression and its correlation with the clinicopathological characteristics of 50 endometrial cancers
Clinicopathological characteristics Negative Positive + ++ +++ ++++
All tumors, n (%) 17 (34.0) 33 (66.0) 9 (18.0) 7 (14.0) 13 (26.0) 4 (8.0)
Tumor grade, n (%)
G1 4 (8.0) 13 (26.0) 4 (8.0) 1 (2.0) 6 (12.0) 2 (4.0)
G2 11(22.0) 16 (32.0) 2 (4.0) 5 (10.0) 7 (14.0) 2 (4.0)
G3 2 (4.0) 4 (8.0) 3 (6.0) 1 (2.0)
Histology, n (%)
Adenocancer 15 (30.0) 29 (58.0) 9 (18) 4 (8.0) 12 (24.0) 4 (8.0)
Adenosquamous cancer 2 (4.0) 4 (8.0) 3 (6.0) 1 (2.0)
-, 5%; +, <25%; ++, 25-50%; +++, 50-75%; ++++ > 75%.
Table 3 Sp17 expression and its correlation with the clinicopathological characteristics of 31 cervical cancers
Clinicopathological characteristics Negative Positive + ++ +++ ++++
All tumors, n (%) 12 (38.7) 19 (61.3) 8 (25.8) 3 (9.7) 7 (22.6) 1 (3.2)
Tumor grade, n (%)
G1 4 (12.9) 5 (16.1) 1 (3.2) 2 (6.5) 2 (6.5)
G2 4 (12.9) 9 (29.0) 4 (19.4) 4 (12.9) 1 (3.2)
G3 4 (12.9) 5 (16.1) 3 (9.7) 1 (3.2) 1 (3.2)
Histology, n (%)
Adenocancer 8 (25.8) 7 (22.6) 4 (12.9) 2 (6.5) 1 (3.2)
Squamous cancer 4 (12.9) 12 (38.7) 4 (12.9) 3 (9.7) 5 (16.1)
-, 5%; +, < 25%; ++, 25-50%; +++, 50-75%; ++++ > 75%.
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study failed to support this presumption.
The Sp17 targeted immunotherapy of tumors remains
controversial and needs more accurate validation. Those
in favor hold that although tumor specificity is an
advantage of the therapy, it is extremely difficult to find
a molecule absolutely specific for tumor vaccines. More-
over, both cancer patients and oncologists are familiar
with and accept the nonspecific toxicities of other anti-
tumor therapies [32,33]. In this regard, this protein may
be a candidate for a gynecological cancer vaccine. How-
ever, in view of the extensive presence of this molecule
in somatic cells, further research to evaluate the suitabil-
ity of Sp17 as a human therapeutic antigen is imperative
before it is used as a molecular target for the treatment
of tumors.
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